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Abstract: Family members provide most of the patient care and administer most of the treatments 
to patients with Alzheimer’s disease (AD). Family caregivers have an important impact on clini-
cal outcomes, such as quality of life (QoL). As a consequence of this service, family caregivers 
suffer high rates of psychological and physical illness as well as social and financial burdens. 
Hence, it is important to involve family caregivers in multimodal treatment settings and provide 
interventions that are both suitable and specifically tailored to their needs. In recent years, sev-
eral clinical guidelines have been presented worldwide for evidence-based treatment of AD and 
other forms of dementia. Most of these guidelines have considered family advice as integral to 
the optimal clinical management of AD. This article reviews current and internationally relevant 
guidelines with emphasis on recommendations concerning family advice.
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Introduction
Alzheimer’s disease (AD) is the most prevalent cause of dementia encountered in older 
patients.1 Late-stage clinical AD can result in substantial clinical burden and a reduction of 
quality of life (QoL) for the patients and family caregivers.2 There are a number of effec-
tive nonpharmacological and symptomatic pharmacological approaches to treat AD. All of 
those approaches, however, cannot prevent, cure or stop the progression of the disease.1,3 
Therefore, the specific goals of current treatments are to preserve cognitive and functional 
ability, minimize behavioral disturbances, slow disease progression, ease the burdens on 
the patient and family, and maintain their QoL through clinical management. In optimal 
management of AD patients, both pharmacological and nonpharmacological treatments 
must be considered necessary and adapted to meet the individual needs of each AD patient 
and their family caregivers.3,4 In this review, we focus on nonpharmacological approaches 
that address family advice as part of an optimal clinical management of AD.
Family caregivers provide most of the patient care and administer most of the treatments 
used for patients with AD.3 They have an important impact on the QoL of dementia patients.5,6 
Further, they suffer high rates of psychological and physical illness, as well as carrying many 
of the social and financial consequences.7 Hence, it is important to involve family caregivers 
in multimodal treatment settings and provide interventions that are directly addressed to the 
family caregivers (eg, education programs, support groups, and counseling).
In recent years, several clinical guidelines for evidence-based treatment of AD 
and other forms of dementia have been published worldwide. Here, we review current 
and internationally relevant guidelines with respect to the given recommendations 
concerning family advice.Neuropsychiatric Disease and Treatment 2010:6 244
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published and internationally accepted dementia guidelines 
with respect to the given recommendations concerning 
family advice.
American Psychiatric Association (APA)
Purpose
According to the authors, the purpose of this guideline was 
to assist the psychiatrist in caring for a dementia patient. 
In particular, the authors sought to summarize data in order 
to inform the care of patients with AD and other forms 
of dementia, including vascular dementia, dementia with 
Parkinson’s disease, dementia with Lewy bodies, and the 
frontotemporal dementia spectrum disorders.10
Contents
The APA practice guideline covered the pharmacological and 
nonpharmacological treatment of dementia patients as well 
as the support for family members and other caregivers.
Synopsis of treatment recommendations
The guideline summarized treatment recommendations for 
cognitive symptoms, psychosis and agitation, depression, 
and sleep disturbances. The authors discussed psychiatric 
management, specific psychotherapies and other psychoso-
cial treatments and provided corresponding recommenda-
tions. In addition, the authors critically considered special 
concerns such as somatic treatments for elderly patients and 
dementia patients, as well as special issues for long-term 
care. In addition, the authors proposed an extensive guide 
to develop and implement a stage-specific treatment plan 
for the individual patient and discussed how specific clinical 
features influence the treatment plan in great detail.
Method
Clinical guidelines were identified via a MEDLINE search 
using MeSH headings, Alzheimer disease AND clinical 
guidelines. The alternative terms, practice guidelines, 
treatment guidelines, consensus guidelines, consensus 
statement, practice parameter, and practice recommenda-
tion were also searched in conjunction with the MeSH 
term, Alzheimer disease. Additionally, MEDLINE was 
searched using the term dementia AND clinical guide-
lines or practice guidelines. All searches were limited to 
articles published in English within the last five years. The 
reference lists of articles thus identified were searched 
manually to identify additional articles of interest. A total 
of 125 unique articles were identified. Based on these 
articles, four internationally relevant clinical guidelines 
for the treatment of patients with AD were identified (see 
Table 1). For this review, we defined clinical guidelines as 
statements that have been systematically developed and 
which aim to assist clinicians in making decisions about 
treatment for specific conditions. Clinical guidelines 
are linked to evidence and are meant to facilitate good 
medical practice.8
Clinical guidelines for the treatment  
of patients with AD
The principal benefit of guidelines is to improve the quality 
of clinical care by providing a robust management strategy 
for patients.9 Guidelines represent an option for improving 
the overall quality of clinical care; nevertheless, they need 
to be interpreted and applied in a way that is clinically 
appropriate.8 Below, we analyze and discuss four recently 
Table 1 Internationally relevant guidelines
Reference Country of 
origin
Editor Target group Contents Recommendation 
of family advice
10 USA American Psychiatric  
Association (APA)
Psychiatrists Treatment of people  
with dementia; Support  
for Caregivers
Yes
11 UK NICE and SCIE General Practitioners, Nurses, Geriatricians, 
Psychiatrists, Social Workers, Care  
Home Managers and Care Staff,  
Commissioners, Managers and  
Coordinators of Health and Social Care
Identification, Treatment  
and Care of people with 
dementia; Support for 
Caregivers
Yes
12 USA American Academy  
of Neurology (AAN)
Neurologists; Other Clinicians who  
manage Patients with Dementia
Treatment of people with 
dementia; Support for 
Caregivers
Yes
13 EU European Federation  
of Neurological  
Societies (EFNS)
Clinical Neurologists; Geriatricians; 
  Psychiatrists; Other specialist Physicians  
responsible for the care of Patients  
with Dementia
Identification, Treatment  
and Care of people with 
dementia; Support for 
Caregivers
YesNeuropsychiatric Disease and Treatment 2010:6 245
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The authors of the APA practice guideline10 declared 
that the guideline is intended to be inclusive and to cover 
the range of necessary treatments that might be used by 
a physician or consultant who provides or coordinates the 
overall care of the dementia patient. They indicated that the 
psychiatrist caring for a dementia patient should consider, 
but need not be limited to, the treatments recommended in 
the practice guideline.
Recommendations concerning family advice
Throughout the entire guideline, the authors emphasized the 
relevance of providing critical support for family members 
and other caregivers and making referrals to social, legal, 
and other community resources. The guideline also notably 
highlighted the role of family advice in optimal psychiatric 
management. The recommended interventions include edu-
cating patients and families about the illness, the course of 
treatment, and sources of additional care and support (eg, sup-
port groups, respite care, nursing homes, and other long-term 
care facilities). Other tasks pertaining to the recommended 
interventions included advising patients and their families of 
the need for financial and legal planning due to the patient’s 
eventual incapacity (eg, power of attorney for medical and 
financial decisions, an up-to-date will, and the cost of long-
term care), and addressing the imminent or eventual need for 
driving cessation with patients and their families due to the 
increased risk of vehicular accidents even in mild dementia. 
Additionally, the guideline denoted the necessity of monitor-
ing the signs of caregiver distress, and the need to support 
families during decisions about institutionalization.
National Institute for Clinical  
Excellence (NICE) – Social Care  
Institute for Excellence (SCIE)
Purpose
The NICE-SCIE guideline’s specific aims were firstly 
to evaluate the role of specific pharmacological agents, 
  psychological and psychosocial interventions in the treatment 
and management of dementia, and secondarily to evalu-
ate the role of specific services and systems for providing 
those services in the treatment and management of dementia. 
The guideline recommended the integration of both of these 
goals to provide best practice advice on the care of individuals 
with a diagnosis of dementia through the different phases of 
illness, including the initiation of treatment, the treatment of 
acute episodes and the promotion of well-being. In addition, 
the authors considered the economic implications of various 
interventions for dementia.11
Contents
The NICE-SCIE guideline covered the assessment and 
diagnosis of dementia, as well as pharmacological and 
  nonpharmacological treatment and care of dementia patients. 
The guideline also indicated that support should be provided 
for family caregivers within primary and secondary health-
care, and social care.
Synopsis of treatment recommendations
The guideline presented a range of recommendations on 
pharmacological and nonpharmacological treatments for 
cognitive symptoms and maintenance of functioning, as 
well as recommendations regarding treatments for noncog-
nitive dementia symptoms. Some recommendations were 
given for educational interventions in dementia patients. 
The authors critically discussed the role of dementia care 
mapping (DCM); and recommended that further systematic 
research be conducted using outcome measures of quality 
of life other than DCM, in order to adequately evaluate 
its impact as a vehicle of change. The authors highlighted 
the impact of staff training and interventions on caregivers 
of dementia patients and the guideline proposed require-
ments for review and evaluation of care plans, adherence 
to ethical principles and assessment of capacity to make 
decisions. The authors provided recommendations regard-
ing how to recognize and respond to suspected abuse and 
neglect, how to approach the topic of workforce develop-
ment, and how to design the environment to be supportive 
and therapeutic. Also identified was the need for acute in-
patient hospital services to address the specific problems 
of dementia patients.
The guideline also emphasized the need for care to be 
  person-centered and the authors recommended a coordinated 
and integrated approach between health and social care services 
to treat and care for dementia patients and their caregivers.
Family advice
The guideline emphasized the imperative in dementia care to 
consider the needs of caregivers, and to consider ways of sup-
porting and enhancing the efforts of caregivers on behalf of 
the dementia patient. The authors emphasized that dementia 
patients are enabled to live longer in their own communities 
when caregivers are well supported and well informed.11
Specifically, the guideline recommended educating the 
family caregivers with written information about the signs 
and symptoms of dementia, the course and prognosis of the 
condition, treatment options, local care and support services, 
and the types of support groups available. It also clarified the Neuropsychiatric Disease and Treatment 2010:6 246
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value of helping the family know where sources of financial 
and legal advice are located, how they may benefit from advo-
cacy, what the relevant medico-legal issues are (ie, such as 
driving cessation), and where other local information sources, 
including libraries and voluntary organizations, are located. 
The authors recommended that there be continuous assess-
ment of family caregivers´ needs in parallel to the design of 
a care plan for family caregivers of dementia patients. This 
may consist of multiple components including: individual 
or group psychoeducation, peer-support groups with other 
caregivers, support and information by telephone and through 
the internet, training courses about dementia, services, com-
munication and problem solving skills in the care of dementia 
patients, as well as involvement of other family members 
and the primary caregiver in family meetings. Additionally, 
the authors proposed some recommendations for practical 
support and services such as, day care, day- and night-sitting, 
adult placement, short-term and/or overnight residential care, 
and transport services.
American Academy of Neurology (AAN)
Purpose
The objective of this guideline was to define and investigate 
key issues in the management of dementia and to make litera-
ture based treatment recommendations. Pharmacologic and 
nonpharmacologic treatments for dementia management were 
addressed in terms of scientifically sound, clinically relevant 
practice parameters to aid in the practice of neurology.12
Contents
The AAN practice parameter “Management of dementia” 
covered the treatment of dementia patients and the sup-
port that should be provided for family members and other 
caregivers.
Synopsis of treatment recommendations
The AAN practice parameter addressed four clinically 
relevant questions regarding the management of dementia: 
Does pharmacotherapy for cognitive symptoms improve 
outcomes in dementia patients compared with no therapy? 
Does pharmacotherapy for noncognitive symptoms improve 
outcomes in dementia patients compared with no therapy? 
Do educational interventions improve outcomes in patients 
and/or caregivers of dementia patients compared with no 
such interventions? Do nonpharmacologic interventions 
other than education improve outcomes in patients and/or 
caregivers of dementia patients compared with no such 
interventions?
The authors presented analysis of evidence and practice 
recommendations for all named issues. Very briefly, the 
guideline put forth three additional issues that were evaluated 
to be important: cooperation amongst neurologists, other cli-
nicians, and community care providers; the impact of differ-
ent economic models of care; and assessments for predicting 
decision-making capacity for dementia patients. With respect 
to these issues, the guideline stated more research is needed 
to derive more specific recommendations.
Family advice
The guideline recommended that specific nonpharmacologi-
cal interventions should be offered to family caregivers to 
improve caregiver satisfaction and to delay the time to nursing 
home placement for the patient with AD. The recommended 
interventions included education (eg, comprehensive, psy-
choeducational caregiver training, short-term programs 
directed toward educating family caregivers about AD, and 
intensive long-term education), support (eg, such as sup-
port groups, telephone support, and other support services 
when available), and respite care (eg, such as adult day care 
for patients and other respite services). Additionally, the 
guideline suggested the use of computer networks to provide 
education and support to caregivers. Moreover, the authors 
stressed that more research is recommended to develop ways 
to match family caregiver interventions to the specific needs 
of family caregivers.
European Federation of Neurological 
Societies (EFNS)
Purpose
The international EFNS guideline on dementia aimed to pres-
ent a peer-reviewed evidence-based statement to guide the 
practice of clinical neurologists, geriatricians, psychiatrists, 
and other specialist physicians responsible for the care of 
dementia patients.13
Contents
The EFNS guideline covered the identification and phar-
macological treatment of dementia patients and briefly 
addressed the support that is necessary to be provided for 
family members and other caregivers.
Synopsis of treatment recommendations
The main emphasis of this guideline was on recommenda-
tions for pharmacological treatment. It offered recommenda-
tions on pharmacological treatments for cognitive symptoms 
and maintenance of functioning, as well as recommended Neuropsychiatric Disease and Treatment 2010:6 247
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treatments for noncognitive symptoms. The authors purposely 
limited their guideline to pharmacological treatments, and 
so many other important aspects of the care for dementia 
patients were intentionally not covered. Nevertheless, a few 
recommendations were given with respect to counseling and 
support for family caregivers, relevant legal issues, problems 
with driving, and the collaboration of specialist physicians 
with other health care professionals.
Family advice
The authors emphasized the relevance of providing counsel-
ing and support for family members and other caregivers; 
however, they did not offer explicit or specific recommenda-
tions for treatment or other forms of intervention. The authors 
indicated that education and information, along with support 
groups for both patients and family caregivers, are all helpful 
with regard to the treatment of behavioral and psychological 
symptoms in dementia. They also suggested that specialist 
physicians assess family caregiver distress and needs at regu-
lar intervals throughout the course of the disease.
Additional guidelines
In the last five years, some additional guidelines have been 
published (see Table 2). Some of those guidelines have a 
priori been developed as national guidelines and others 
focus only on pharmacological treatments of dementia and 
are therefore not relevant for this article. Nevertheless, these 
guidelines are valuable for the further enhancement of inter-
national guidelines, and in particular, for the improvement of 
national clinical management of AD. These other guidelines 
are also statements that have been systematically developed, 
linked to evidence, and that were meant to facilitate good 
medical practice. Therefore, they can be classified as clinical 
guidelines.
Link to evidence
All the guidelines considered in this review prove to be 
linked to empirical evidence. Regarding the four guidelines 
considered relevant to this article, we find that the guideline 
development process was traceable and that certain levels of 
evidence for the given recommendations have been defined. 
However, we also note that several guidelines specifically 
reviewed herein did not consistently correlate each of the 
provided recommendations with a statement of the strength 
of the underlying evidence.
For the AAN and EFNS guidelines, the level of evidence 
is readily identifiable since it is always mentioned in 
  combination with the given recommendation.
In particular, the AAN guideline defined three levels of 
evidence:
Standard Principle for patient management that reflects 
a high degree of clinical certainty,
Guideline Recommendation for patient management that 
reflects moderate clinical certainty,
Practice Option Strategy for patient management for 
which the clinical utility is uncertain.12
The EFNS guideline graded the recommendations 
according to the strength of evidence, using the definitions 
given in the EFNS guidance:
Level A rating established as useful/predictive or not 
useful/predictive,
Level B rating established as probably useful/predictive 
or not useful/predictive,
Level C rating established as possibly useful/predictive 
or not useful/predictive.19
The APA guideline began with an executive summary in 
which treatment recommendations were coded according to 
three levels of degree of clinical evidence:
[I]   Recommended with substantial clinical confidence,
[II]  Recommended with moderate clinical confidence,
[III]    May be recommended on the basis of individual 
circumstances.10
To identify the strength of the underlying evidence of a 
recommendation given in the associated sections of the APA 
guideline, one can examine the listing of cited references. 
Each reference was followed by a letter code in brackets 
that indicated the nature of the supporting evidence. The 
guideline allows the reader to appreciate the evidence base 
behind the guideline recommendations and the weight that 
should be given to each recommendation. The initial execu-
tive summary provided a clear overview about the levels of 
evidence.
The NICE-SCIE guideline used four components (study, 
design/quality, consistency and directness) to produce an 
Table 2 Additional guidelines selected
Reference Country of origin Editor
35
14
Canada Canadian Medical  
Association (CMA)
15 Germany DGPPN and DGN
16 USA ACP and AAFP
17 Brazil Brazilian Academy  
of Neurology
18 Italy Italian Association  
of PsychogeriatricsNeuropsychiatric Disease and Treatment 2010:6 248
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overall quality of evidence grade. The following definitions 
were used:
High    Further research is very unlikely to change our 
confidence in the estimate of the effect,
Moderate    Further research is likely to have an important 
impact on our confidence in the estimate of the 
effect, and may change the estimate,
Low    Further research is very likely to have an impor-
tant impact on our confidence in the estimate of 
the effect, and is likely to change the estimate,
Very low  Any estimate of effect is very uncertain.11,20
In this guideline, each recommendation was followed by a 
referencing note; for example, ‘for the evidence, see section 6.3’. 
In this section, the reader finds a factual, well-supported rationale 
for the recommendation. To prove the underlying evidence of a 
citation, the reader can further search for the respective profile 
table in an appendix, which is published as a substantive vol-
ume with accompanying CD-ROM. This CD-ROM includes 
the full results of evidence assembly and synthesis, including 
search details, pharmacological interventions, and evidence 
tables based on meta-analyses and narrative summaries for 
psychological interventions (eg, cognitive stimulation, life 
review, light therapy). However, there is no such information 
given for recommendations concerning family advice. Hence, 
the strength of the underlying evidence for most of the recom-
mendations relevant for this article cannot be derived out of the 
NICE-SCIE guideline.
Family advice in the context of optimal 
clinical management
All of the reviewed guidelines presented the consistent 
demand for interventions that include family advice. Further, 
at least three of the four guidelines underscored that family 
advice has potential to ease the burdens on the patient and 
family and to increase their QoL.10–12 In contrast to the other 
guidelines, the EFNS guidelines scarcely mentioned family 
advice, mainly due to the scope and limitations described 
therein. Family advice was considered more or less compre-
hensively in the AAN guideline and was given high attention 
in the APA and NICE-SCIE guidelines.
The various guidelines recommended similar interven-
tions as part of an optimal clinical management of AD; how-
ever, they did not agree on the specific strategies of advising 
families. This difference makes some sense in light of the fact 
that the guidelines target diverse professional groups. Besides 
the problem of different target groups, another explanation 
for this difference is that family advice research has limited 
randomized controlled trial evidence for the specific effects 
of interventions. For example, the authors of the guidelines 
had to extrapolate many recommendations from controlled 
or even uncontrolled clinical trials with small samples. 
Therefore, we see that the authors of the guidelines often 
have had to work with uncertain data; and even when the 
data are certain, recommendations for or against interven-
tions will involve subjective value judgments.9 There appears 
to be susceptibility to bias in the guidelines that is based on 
the nature of evidence, subjective clinical opinion, and level 
or nature of clinical experience in the composition of the 
guideline development group. This susceptibility for bias 
may confound the validity of guidelines.8,9,21 Although the 
methodological quality, design and implementation of family 
caregiver intervention studies continues to improve over time, 
drawing comparisons between studies and making practi-
cal applications remains difficult due to the use of a wide 
range of different outcome domains and measures.7,11,22 For 
example, it is often difficult to discern whether two interven-
tion programs share common features or if different outcomes 
are comparable.11 The problems mentioned above are not to 
suggest the guidelines are ungrounded, but rather provide 
impetus for further high quality research. For example, there 
is a critical need for well designed, randomized, controlled 
trials of potential interventions that examine family advice 
specifically, and that standardize the use of outcome domains 
and measures.
In order to provide a systematic basis for research 
on those interventions, the following sections survey the 
  recommended interventions that include family advice with 
respect to their current level of evidence. We derived five 
types of interventions: Education, counseling, assessment 
of family caregiver distress and needs, practical support 
and services, and psychosocial interventions for dementia 
patients. If available, the levels of evidence documented in 
each guideline, are integrated into the listed recommenda-
tions. In terms of the NICE-SCIE guideline, only the levels of 
evidence for the recommendations concerning psychological 
interventions can be considered. Further recommendations of 
the NICE-SCIE guideline will be listed even though no infor-
mation about the levels of evidence has been provided.
As mentioned above, the four guidelines have used differ-
ent definitions for the levels of evidence. To simplify matters, 
we suggest the following descriptors for levels of evidence, 
which are integrated into three levels (see Table 3):
Level 1 substantial clinical certainty,
Level 2 moderate clinical certainty,
Level 3 uncertain clinical utility.Neuropsychiatric Disease and Treatment 2010:6 249
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The original classifications of the guidelines for the five 
types of interventions that include family advice can be found 
in Table 4. We do not perform a meta-analysis, but present 
the recommendations and the classified levels of evidence, if 
available, in a narrative way for particular types of interven-
tions that include family advice.
Education
All guidelines recommended educational interventions for 
  families that can be conducted for individuals or groups. 
The classified levels of evidence differ from level 1 to 
level 2.10,12,13
According to the APA (2007) and NICE-SCIE (2007) 
guideline, the following contents should be included in edu-
cational interventions: information about the illness, available 
treatments and medication management, local care and sup-
port services, basic principles of care, communication and 
problem solving in the care of dementia patients.
Education can be provided via psychoeducation or skills 
training support groups, in which caregivers may learn from 
one another; or conjunctively via written information and 
telephone and internet-based systems for additional provision 
of information and support.10–13 Furthermore, it may be useful 
to take into account basic cultural and gender differences in 
approaches to caring when designing educational interven-
tions for family caregivers.10,11 However, it is worth noting 
that when educational interventions are introduced at an early 
stage after establishment of the diagnosis, those who provide 
treatment for family caregivers of dementia patients should 
be aware of the possibility that education about dementia may 
sometimes have an adverse effect on a caregiver’s anxiety.11 
The AAN guideline differentiated the effects of short- and 
long-term programs. Short-term programs directed toward 
educating family caregivers about AD should be offered to 
improve caregiver satisfaction; whereas, intensive long-term 
education and support services should be offered to care-
givers of patients with AD to delay time to nursing home 
placement.12
The NICE-SCIE guideline highlighted that information 
is the most useful when dementia patients were involved in 
the educational process. Therefore, the authors recommended 
that care providers consider involving dementia patients in 
psychoeducation, support, and other meetings for family 
caregivers.11
Table 3 Integrated levels of evidence
Integrated for this article APA NICE EFNS AAN
Level 1: substantial clinical certainty Level [I] Evidence grade [High] [Level A rating] Level [Standard]
Level 2: moderate clinical certainty Level [II] Evidence grade [Moderate] [Level B rating] Level [Guideline]
Level 3: uncertain clinical utility  Level [III]  Evidence grade [Low] and Evidence 
grade [Very low]
[Level C rating]  Level [Practice option] 
Table 4 Levels of evidence for interventions that include family advice
Intervention APA NICE EFNS AAN
Education Level [I] Recommended; no  
access to evidence 
rating
[Level B 
rating]
Level [Guideline]
Counseling Level [II] Recommended; no 
access to evidence 
rating
[Level B 
rating]
Level [Guideline]
Assessment of caregiver  
distress and Needs
Recommended; no  
access to evidence 
rating
Recommended; no 
access to evidence 
rating
[Level C 
rating]
No recommendation; 
Call for research
Practical support and services Recommended; no  
access 
to evidence rating
Recommended; no 
access to evidence 
rating
Level [Practice options]
Psychosocial interventions for dementia patients
• Behavioral approaches Level [II] Recommended; no 
access to evidence 
rating
Level [Guideline]
• Stimulation-oriented treatments Level [II] Evidence grade [Moderate] Level [Guideline]
• Reminiscence and validation therapy Level [III] Evidence grade [Moderate]   No RecommendationNeuropsychiatric Disease and Treatment 2010:6 250
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Counseling
All guidelines recommended counseling interventions for 
families. The APA guideline classified the evidence for those 
interventions as level 1; the EFNS classified it as level 2.10,13 
The AAN guideline combined recommendations pertaining 
to counseling interventions and educative interventions; 
and although these constructs seem related and can overlap, 
it is more tedious to distinguish the recommendations that 
are unique to counseling due to the lack of separation of the 
different types of interventions. As mentioned above, the 
evidence for education, which again includes counseling, is 
classified as level 2.
Although counseling includes the provision of informa-
tion, it is more than education alone. Counseling also serves 
to provide emotional support and to help people make their 
own decisions and plan their future actions. Another impor-
tant aspect to counseling as part of optimal clinical manage-
ment pertains to referrals for financial and legal advice due 
to the patient’s eventual incapacity (eg, power of attorney 
for medical and financial decisions, an up-to-date will, and 
financial planning for the cost of long-term care).10,11 Fur-
thermore, patients and families need to be informed about the 
potential and inevitable safety issues. For example, it is not 
uncommon for accidents to occur due to forgetfulness, such 
as fires during the cooking of meals; and there is increased 
risk of vehicular accidents, even in mild dementia. As such, 
driving cessation is an inevitable event for which patients 
with AD and their family caregivers must be prepared.10,11 
In addition, the APA guideline recommended counseling 
for families during decisions about institutionalization. The 
EFNS guideline provided recommendations pertaining to 
legal issues and driving, but did not specify legal and safety 
issues as essential information for counseling. The AAN 
guideline mentioned neither financial and legal issues nor 
driving and safety issues; and it did not offer recommenda-
tions with regard to what the specific tasks of counseling 
should be. The American Academy of Neurology published 
a specific guideline concerning the risk of driving in patients 
with AD.23 However, the need to advise the family about the 
safety issues related to driving was also not clearly covered 
in this specific guideline.
Assessment of caregiver  
distress and needs
The NICE-SCIE, APA and EFNS guidelines identified the 
necessity of assessing caregiver distress and needs at regular 
intervals throughout the course of the disease. The EFNS 
guideline was the only guideline that we found documented 
a level of evidence for this recommendation at level 3.
Additionally, the NICE-SCIE guideline recommended 
that assessing distress and identifying needs of family care-
givers are important to the design of a care plan for family 
caregivers of dementia patients.
The APA guideline further recommended some interven-
tions that have been developed to ease the distress associated 
with long-term care-giving. These interventions include psy-
choeducational programs for improved emotional coping with 
frustration or depression, psychotherapy focused on alleviating 
symptoms of depression and anxiety, exercise interventions for 
caregivers, workshops in stress management techniques, and 
support groups that combine education with support. We did not 
find any level of evidence documented for those recommenda-
tions, but the cited studies imply an evidence level of 2.
The AAN guideline did not explicitly recommend the 
assessment of caregivers’ distress and needs, but called for 
research to develop ways to match caregiver interventions 
to the specific needs of caregivers.12
Practical support and services
An additional component of family advice is the information 
about sources of practical support and services. All guidelines 
recommended various services to be introduced to families, 
such as respite services, nursing homes, other long-term 
care facilities, day care, day- and night-sitting services, 
and short-term and/or overnight residential care. The AAN 
guideline classified the evidence for practical support and 
respite services as level 3.12 Based on the statements of the 
APA guideline, there is mixed evidence for practical support 
and services aside from a clear Level 1 evidence statement 
for the recommendation that care should be organized to 
meet the needs of patients.13
Psychosocial interventions  
for dementia patients
Three of the four considered guidelines recommended some 
psychosocial interventions that are tangent to family advice, 
as the organization or implementation of these interventions 
often falls on the family caregivers.10–12 All of the reviewed 
guidelines concluded that there is limited evidence (from 
randomized controlled trials) regarding the specific effects of 
psychosocial interventions on dementia patients. Neverthe-
less, the reviewed guidelines have provided recommendations 
for interventions. Behavioral approaches, and stimulation-
oriented treatments (eg, recreational activity, art therapy, 
music therapy, and pet therapy) are recommended with Neuropsychiatric Disease and Treatment 2010:6 251
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level 2 evidence.10–12 Furthermore, supportive psychotherapy 
is recommended to address issues of loss in the early stages 
(level 2 evidence).10 Cognition-oriented treatments, such as 
reality orientation, cognitive retraining, and skills training 
focused on specific cognitive deficits, are not recommended 
since they are unlikely to have a persistent benefit and have 
been associated with frustration in some patients.10,11 The 
levels of evidence for reminiscence and validation therapy 
are not consistently classified in the guidelines (NICE-SCIE: 
level 2 evidence; APA: level 3 evidence).10,11
Potential benefits and limitations 
of clinical guidelines
The principal benefit of guidelines is to provide a robust man-
agement strategy for patients, and thus improve the quality 
and consistency of care received by patients.8 With evidence-
based guidelines, the quality of clinical decisions can be 
improved, and authoritative recommendations can reassure 
practitioners about the appropriateness of their treatment 
policies.9 However, guidelines need to be interpreted and 
applied in a way that is clinically appropriate.8 Awareness of 
a treatment’s effectiveness does not confer knowledge about 
how to use that treatment.24 Good evidence can lead to bad 
practice if it is applied without clinical acumen or without 
therapeutic empathy.25 All of the guidelines presented herein 
concluded that the care of every dementia patient must be 
individualized to meet the unique needs of that patient and 
his or her family caregivers.10–13
Multidisciplinary cooperation
Although it can be assumed that clinical practice guidelines 
should improve the quality of care, it is less clear whether they 
actually achieve this goal in daily practice.9,26 The majority of 
interventions that include family advice require special and 
diverse competencies that cannot be assumed for all users of 
a guideline. Multidisciplinary cooperation is needed in order 
to effectively apply the evidence-based interventions recom-
mended in these guidelines in the context of clinical practice. 
Accordingly, the APA, EFNS, and NICE-SCIE guidelines 
recommended a multidisciplinary approach in the treatment of 
dementia, and assumed this as a matter of course for optimal 
clinical management.10,11,13 However, there is a lack of evi-
dence-based articles concerning this issue. As such, the AAN 
guideline formulated recommendations for future research. 
According to the AAN guideline, more research is needed to 
define the roles of various types of practitioners (eg, neurolo-
gists, psychiatrists, geriatricians, primary care physicians) in the 
care of dementia patients. The AAN guideline suggested that 
the benefits of an interactive care approach involving multiple 
practitioners, including cost-benefit assessments, must be stud-
ied.12 Furthermore, the AAN guideline postulated that research 
leading to guidelines for the cooperation between clinicians is 
needed because AD is a chronic illness requiring coordinated 
management that can adapt over the course of the illness.12
The NICE-SCIE guideline explicitly recommended 
strategies to improve coordination and integration of health 
and social care. It recommended that health and social care 
managers should coordinate and integrate work efforts across 
all agencies involved in the treatment and care of people with 
dementia and their family caregivers, including common 
agreement of written policies and procedures.11 Furthermore, 
the NICE-SCIE guideline postulated that joint planning should 
include local service users and family caregivers in order to 
highlight and address problems specific to each locality.11
The assignments of “care managers” and “care coordi-
nators” are promising approaches to ensure the coordinated 
delivery of health and social care services for dementia 
patients. Future research is needed to show how multidisci-
plinary cooperation is best achieved and whether multidis-
ciplinary cooperative approaches to intervention will lead to 
the intended improvements in treatment outcomes for patients 
with AD and their family caregivers.
The problem of treatment 
implementation
In published dementia caregiver intervention research, 
there has been a widespread failure to measure whether the 
implementation of treatment has been effective because 
there is a lack of empirical research regarding implementa-
tion strategies and outcomes.27 The same appears to be true 
of the clinical guidelines. The effect of clinical guidelines 
on medical practice and their impact on patient care is 
often limited.28,29 Hence, guideline development needs to be 
complemented by evidence-based implementation.30
All considered guidelines have given evidence based 
recommendations, which allows for better practice than 
recommendations not based on scientific evidence.31 The 
NICE-SCIE and APA guidelines provided precise definitions 
of recommended performance, which can improve the use of 
guidelines according to Grol and colleagues.31
Although the NICE-SCIE guideline formulated pre-
cise recommendations for local implementations as well 
as details about how the implementation can be audited, 
it also recommended the development of a more broadly Neuropsychiatric Disease and Treatment 2010:6 252
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based implementation strategy.11 None of the other research 
guidelines considered relevant to this article gave recom-
mendations for local or national implementations and 
auditing of the guidelines. The APA guideline formulated 
recommendations for the implementation of a treatment plan, 
which is necessary, but not sufficient for local or national 
implementations.
Conclusion
Evidence-based clinical guidelines have become a major 
feature in health care. Researchers and clinicians in many 
countries have established programs to summarize the evi-
dence for managing AD and other dementias. According to 
current evidence, interventions that include family advice are 
an essential part of an optimal clinical management of AD. All 
of the considered guidelines agree on the potentially positive 
effects of family advice on dementia patients and their family 
caregivers with medium range levels of evidence.
However, guideline recommendations are frequently not 
applied in practice.32 As such, many patients do not profit from 
evidence-based insights.33 Practitioners need special skills in 
order to apply the interventions recommended in the guidelines 
concerning family advice. For example, skills such as leading 
a psychoeducational training group cannot be assumed for all 
types of practitioners. Hence, it seems important to provide 
education for practitioners about how to change their clinical 
practice in order to take into account the recommendations given 
in the clinical guidelines (eg, how to successfully realize the 
recommendations of the guidelines in a multidisciplinary team 
setting). In order to address the needs of the end user of a guide-
line, caregiver education materials and practical tools to manage 
family advice in practice should be provided to practitioners.34
Research that addresses the clinical problem of how to 
apply the clinical guidelines and evidence-based interventions 
practically is clearly needed to increase the use of the guide-
lines in clinical practice and to improve the management of 
patients with AD and their family caregivers.
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